Phase II Clinical Trial: Ex Vivo Drug Sensitivity Testing in Parallel with Physician Selected Selinexor-Based Therapy for Multiple Myeloma
Zachary J. Walker(University of Colorado Anschutz Medical Campus), Daniel W. Sherbenou(University of Colorado Anschutz Medical Campus), Lauren T. Reiman(University of Colorado Anschutz Medical Campus), Peter A. Forsberg(University of Colorado Denver), Alfonso Roque(University of Colorado Anschutz Medical Campus), Sarah E. Parzych(University of Colorado Anschutz Medical Campus), Deng Wang(Shanghai Jiao Tong University), Jacob Joram(University of Colorado Anschutz Medical Campus), Meghan Straubel(University of Colorado Anschutz Medical Campus), Kaylynn Imsande(University of Colorado Anschutz Medical Campus), Katie Zhou(University of Colorado Anschutz Medical Campus)
Cited by 1
Related Papers
Disruption of IRE1α through its kinase domain attenuates multiple myeloma
|Proceedings of the National Academy of Sciences|2019|115
Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer
|Cell Death and Differentiation|2024|47
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
|Journal of Hematology & Oncology|2024|46
Effect of Autologous Bone Marrow Stem Cell Therapy in Patients with Liver Cirrhosis: A Meta-analysis
|Journal of Clinical and Translational Hepatology|2019|29